SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66
Search This Board:
Last Post: 7/27/2016 12:05:20 PM - Followers: 536 - Board type: Free - Posts Today: 2

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations
Office: 941-637-9883

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director

Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Ownership (sc 13g) 02/16/2016 06:20:13 AM
#41436   Where did all the $$ go Gerald did Dip66 07/27/16 12:05:20 PM
#41434   How long will the CEO hide for Dip66 07/26/16 09:00:40 PM
#41433   MCET shareholders had enough of the lies - Dip66 07/26/16 08:59:00 PM
#41432   New office number: 941-637-9883 Dip66 07/26/16 12:46:23 PM
#41431   Barbara Corbett running art business behind the backs Dip66 07/26/16 12:45:31 PM
#41430   Barbara Corbett selling art on Twitter - Dip66 07/26/16 12:43:48 PM
#41429   MultiCell getting into the art business - Dip66 07/26/16 12:42:55 PM
#41428   Keep stirring the pot fellows. Keep stirring mrroundtree 07/25/16 09:47:47 PM
#41427   Doesn't seem to have anything to do with simon wagstaff 07/25/16 04:12:46 PM
#41426   And it goes on! The future advances in TPX 07/25/16 10:20:38 AM
#41425   Beware Adam Feuerstein and hype pphm_mike 07/24/16 08:15:43 PM
#41424   Yet they can't even afford a phone line. simon wagstaff 07/24/16 05:33:41 PM
#41422   Mammatyper Seen to Ably Classify Invasive Breast Cancers, TPX 07/22/16 11:12:49 AM
#41421   Who is it that puts together all this simon wagstaff 07/22/16 05:38:16 AM
#41420   Gotta love how MultiCell keeps slapping the ask Dip66 07/21/16 04:46:15 PM
#41419   I was trying to be honest and factual. simon wagstaff 07/21/16 05:25:04 AM
#41418   Jan 14th of this year bontooth 07/21/16 12:16:34 AM
#41417   Is .0009 the price your looking to cover Dip66 07/20/16 03:35:45 PM
#41416   5 million shares is just about tank of simon wagstaff 07/20/16 02:50:44 PM
#41415   CEO dumping more shares to keep his boat Dip66 07/20/16 02:29:18 PM
#41414   Lol! There's just no stopping MCET and simon wagstaff 07/20/16 10:21:00 AM
#41413   The future advances in things ADC immunotherapy! TPX 07/19/16 07:43:12 AM
#41412   Triple-negative breast cancer target is found TPX 07/15/16 03:40:40 PM
#41411   Drug found that significantly slows growth of most TPX 07/15/16 03:32:36 PM
#41410   MCIT: More info about ADC product candidate ADC TPX 07/15/16 03:11:36 PM
#41409   If you read it you will see it simon wagstaff 07/15/16 01:08:26 PM
#41408   MultiCell Immunotherapeutics: Global Therapeutic Antibody Bundle Report 2016 TPX 07/15/16 12:47:35 PM
#41407   Work hard will be rewarded each other! Oxis TPX 07/15/16 12:03:42 PM
#41406   Oxis has gone from $3.70 to .31 in simon wagstaff 07/15/16 11:54:24 AM
#41405   What was again? Again as a reminder! TPX 07/15/16 11:38:02 AM
#41404   Yes very interesting reading The dead cat bouncer 07/15/16 11:25:05 AM
#41403   You can block him if you don't want computerguy101 07/15/16 09:42:25 AM
#41402   MCET doesn't have money to file reports any simon wagstaff 07/15/16 09:00:37 AM
#41401   Yes, most amusing. simon wagstaff 07/15/16 08:40:59 AM
#41398   Keep them coming TPX. Interesting reading MyDogBuster 07/15/16 07:27:10 AM
#41397   Buy more shares, they are cheap. Back up simon wagstaff 07/15/16 06:37:07 AM
#41396   Antibody Drug Conjugates Market (3rd Edition), 2015-2025 TPX 07/15/16 05:36:35 AM
#41395   You have proved it where. In you MyDogBuster 07/14/16 10:10:12 PM
#41394   OK, sell Oxis. simon wagstaff 07/14/16 08:00:34 PM
#41393   I have. Prove otherwise. simon wagstaff 07/14/16 07:50:24 PM
#41392   Well I do not know why you think The dead cat bouncer 07/14/16 06:47:54 PM
#41391   Prove it MyDogBuster 07/14/16 01:40:01 PM
#41390   Not negative, factual. MCET is doing nothing. "Hard simon wagstaff 07/14/16 12:01:31 PM
#41389   MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics ent TPX 07/14/16 09:01:07 AM
#41388   ADC INFO! MCET and OXIS! About / Technology TPX 07/14/16 08:44:25 AM
#41387   [bOXIS International, Inc. (OXIS) Could Hold The Key redsox17 07/14/16 07:56:52 AM
#41386   TPX - Keep up the good work MyDogBuster 07/14/16 04:53:36 AM
#41385   WHAT ARE ANTIBODY-DRUG CONJUGATES? TPX 07/14/16 04:50:32 AM
#41384   MultiCell Immunotherapeutics, Inc.: OXIS International, Inc. (OXIS) Could TPX 07/14/16 04:31:18 AM